New scan could spot lung scarring early in fibrosis and cancer patients

NCT ID NCT03535545

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing a new imaging agent called [68Ga]CBP8 to see if it can safely and accurately detect collagen buildup (scarring) in the lungs. Researchers will compare scans from healthy volunteers, lung cancer patients, and people with pulmonary fibrosis. The goal is to improve diagnosis and track disease progression over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiolitis obliterans syndrome idiopathic pulmonary fibrosis interstitial lung disease lung cancer lung neoplasm non-small cell lung carcinoma pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

    Contact